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A number of medicines are currently under investigation for the treatment of COVID-19
disease including anti-viral, anti-malarial, and anti-inflammatory agents. While these
treatments can improve patient’s recovery and survival, these therapeutic strategies do
not lead to unequivocal restoration of the lung damage inflicted by this disease. Stem
cell therapies and, more recently, their secreted extracellular vesicles (EVs), are emerging
as new promising treatments, which could attenuate inflammation but also regenerate
the lung damage caused by COVID-19. Stem cells exert their immunomodulatory,
anti-oxidant, and reparative therapeutic effects likely through their EVs, and therefore,
could be beneficial, alone or in combination with other therapeutic agents, in people
with COVID-19. In this review article, we outline the mechanisms of cytokine storm
and lung damage caused by SARS-CoV-2 virus leading to COVID-19 disease and
how mesenchymal stem cells (MSCs) and their secreted EVs can be utilized to tackle
this damage by harnessing their regenerative properties, which gives them potential
enhanced clinical utility compared to other investigated pharmacological treatments.
There are currently 17 clinical trials evaluating the therapeutic potential of MSCs for the
treatment of COVID-19, the majority of which are administered intravenously with only
one clinical trial testing MSC-derived exosomes via inhalation route. While we wait for the
outcomes from these trials to be reported, here we emphasize opportunities and risks
associated with these therapies, as well as delineate the major roadblocks to progressing
these promising curative therapies toward mainstream treatment for COVID-19.
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GRAPHICAL ABSTRACT | Mesenchymal stem cells and their secreted extracellular vesicles are capable of abrogating inflammation and inducing lung regeneration,
which can improve recovery of the patients hospitalized with COVID-19.
UNDERSTANDING CORONAVIRUSES AND
THEIR IMPACT ON HEALTH
A new strain of coronavirus, SARS-CoV-2 (severe acute
respiratory syndrome coronavirus 2, as named by the
International Committee on Taxonomy of Viruses) discovered
in Wuhan, China, in December 2019, has caused a global
disruption and COVID-19 pandemic. SARS-CoV-2 is classified
as Betacoronavirus. In general, coronavirus is the name of viruses
that belong to the family Coronaviridae. These are classified
into four categories: Alphacoronavirus, Betacoronavirus,
Gammacoronavirus, and Deltacoronavirus. Alpha- and
betacoronaviruses infect mammals, gammacoronaviruses infect
avian species, and deltacoronaviruses infect both mammalian
and avian species (Li, 2016). Coronaviruses are typically
spherical, fatty enveloped viruses, which encapsulate large single-
stranded RNA genomes, notably, the largest genome among all
RNA viruses, typically ranging from 27 to 32 kb. The genome
is packed inside a helical capsid formed by the nucleocapsid
protein (N) and further surrounded by the envelope.
Coronaviruses have characteristic clove-shape spikes
(“corona”) protruding from the surface. The spikes are protein
complexes that virus uses to bind to a receptor (receptor-binding
subunit S1) and mediate entry into host cells (a membrane-
fusion subunit S2). Upon binding virus fuses with the human cell
membrane, allowing the genome of the virus to enter the cell and
begin replication. The receptor-binding domain of SARS-CoV-2
spikes are closely related to those of SARS-CoVs (73.8–74.9%
amino acid identity) and SARS-like CoVs (75.9–76.9% amino
acid identity) (Wu et al., 2020). SARS-CoV-2 uses the human
angiotensin I converting enzyme 2 (ACE2) receptor for cell entry
(Lu et al., 2020), which could potentially facilitate human-to-
human transmission. In addition to mediating virus entry, the
spike feature is a critical determinant of viral host range and
tissue tropism and a cause of host immune responses.
Since the ACE2 receptor is widely distributed on the human
alveolar type II cells and capillary endothelium (Hamming et al.,
2004), lungs are particularly susceptible to the SARV-CoV-2
infections. Indeed, recent studies demonstrated that the disease
could affect a large portion of the lungs causing widespread
damage (Figure 1), which subsequently may lead to permanent
changes to the lung function. Recent MRI study of a 59-year old
male patient diagnosed with COVID-19 showed that the disease
is not confined to any particular area, but that it can spread
across the entire lungs (Figure 1; Mortman, 2020). However, this
is not caused directly by the virus, but rather the host immune
response leading to overwhelming cytokine storm in the lungs.
The overexpression of cytokines such as IL-2, IL-6, IL-7, GSCF,
IP10, MCP1, MIP1A, and TNFα is followed by edema, which
impairs oxygen exchange, and may lead to acute respiratory
distress syndrome (ARDS) causing potential acute cardiac injury,
secondary infection (Huang et al., 2020), and death.
Most recent observations suggest that the devastating
complication of COVID-19 may not be a typical pneumonia
or ARDS, but rather a dysfunction in blood oxygenation. This
statement is supported by the fact that over 80% of COVID-19
patients placed on ventilators in New York City have died (Baker,
2020). According to Dr. Cameron Kyle-Sidell (Maimonides
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FIGURE 1 | Widespread distribution of the areas affected by COVID-19 and the effects of stem cells and extracellular vesicles on the recovery of lung function.
Medical Center, New York, March 31, 2020), COVID-19 patients
show symptoms associated with high altitude without adaptation
response (Gattinoni et al., 2020a,b). Clinically these cases
resemble more closely high-altitude sickness characterized by
decompression pulmonary sickness or high-altitude pulmonary
edema (HAPE) with distinctive features of severe hypoxemia
often associated with near normal respiratory system compliance.
Since cytokines and inflammation play dominant role
in the development of COVID-19-induced lung damage,
immunological therapies capable of attenuating cytokine storm
may be the key treatment options. However, traditional
immunomodulatory capacity of common immunotherapeutics
are targeted at one or two factors, which may not induce a strong
enough response.
Mesenchymal stem/stromal cells (MSCs) have demonstrated
potent and broad immunomodulatory and anti-inflammatory
capacity (Abdi et al., 2008; Wada et al., 2013). Therefore, MSC-
based therapy could potentially be an effective treatment for
COVID-19. Notably, due to their regenerative properties (Mahla,
2016), MSCs can promote the repair of damaged tissue, in
order to prevent long-term lung damage inflicted by COVID-
19. Importantly, MSCs have been shown to stabilize endothelial
fluid leakage and maintain alveolar-capillary barrier function,
which is vital to sustain or decrease lung permeability due to
inflammation, thus attenuating the development of interstitial
lung edema (Bhattacharya and Matthay, 2013).
ARE WE ALL AFFECTED THE SAME WAY
BY CORONAVIRUS?
Coronavirus-related infections can cause a variety of illnesses,
which range from asymptomatic or mild such as a common cold,
to severe including Severe Acute Respiratory Syndrome (SARS),
Middle East Respiratory Syndrome (MERS), and now, COVID-
19. The severity of these infections also varies widely between
age-groups and different ethnic populations. Older people are at
increased risk of acquiring the infection and are likely to develop
severe symptoms culminating in death.
Interestingly, there appears to also be gender disparity in the
number of acquired cases of COVID-19 with higher percentage
of men (∼60%) than women being infected, as was first reported
in China (Li et al., 2020); other countries have also reported
higher case fatality rate (CFR) in men1. Similar observations
were reported in a meta-analysis in relation to the MERS-CoV,
where the number of infected men was double that of females
(Badawi and Ryoo, 2016). Epidemiological studies tracing SARS-
CoV showed that SARS-CoV was also more prevalent in men
and associated with increased CFR (Karlberg, 2004). A number
of proposed explanations for these gender differences in terms
of both the incidence and CFR of MERS-CoV, SARS-CoV,
and now COVID-19 infections, include past smoking history,
work-environmental factors, different treatment regimens, and
underlying biological differences such as gender-specific innate
and adaptive immune responses (Karlberg, 2004; Klein and
Flanagan, 2016). Clear biological differences between male and
female gender include the presence of different steroid hormones
and two instead of one X-chromosomes in females, which
influences the number of immune response X-linked genes and
genetic susceptibility to viral infections (Klein and Flanagan,
2016). Notably, experiments in mice, which seem to represent
responses in humans well in this particular study, demonstrated
greater susceptibility of male mice to enhanced viral titres,
vascular leakage, and alveolar edema, compared to age-
matched female mice infected with SARS-CoV (Channappanavar
et al., 2017). This was attributed to differential immune cells
and inflammatory responses including inflammatory monocyte
macrophages, neutrophils, T- and B-cells. Notably, in this pre-
clinical study, sex-dependent differences in susceptibility to
SARS-CoV infection became more prominent with advancing
1COVID-19 Sex-Disaggregated Data Tracker. Global Health 5050.
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age. In fact, once female mice underwent ovariectomy or
were administered estrogen receptor antagonist treatment,
the mortality associated with SARS-CoV infection increased,
suggesting a protective effect of estrogen receptor signaling.
Although experimental and mechanistic data is lacking in
relation to the novel COVID-19 sex-specific differences, it is
likely that similar factors and biological differences will be
applicable as with MERS-CoV and SARS-CoV. It is important
for these differences to be clearly elucidated particularly in
the context of the treatment response, with certain treatments
potentially being more effective in a specific gender group.
Nevertheless, other confounding factors need to be taken into




Despite over 300 active and recruiting clinical trials and a number
of trials already completed, there is still no robust evidence that
any of the investigated therapeutics are effective as treatments
for COVID-19 disease (Channappanavar et al., 2017). Equally,
there is no evidence to support prophylactic treatment either
(Sanders et al., 2020). However, there are only 29 trials in
adult patients with placebo-controlled arm (Channappanavar
et al., 2017). Various types of pharmacological treatments are
currently under investigation including anti-viral, anti-malarial
and anti-inflammatory agents. These therapies generally target
the following processes: (1) the entry of the virus into host
cells, (2) multiplication of the viral genetic material, and (3)
immune response/inflammation. Most of these agents have been
previously used as treatments for SARS-CoV and MERS-CoV,
however the overall conclusions of the meta-analyses published
in 2006 and 2018, respectively, did not support the use of
any particular regimen. In relation to the meta-analysis of
SARS-CoV treatments, the authors systematically reviewed 54
treatment studies, 15 in vitro studies and three ARDS studies
(Stockman et al., 2006). Although the combination of ribavirin
and interferon-based (IFN) treatments appears the most effective
for MERS (Morra et al., 2018), this needs to be confirmed
in randomized placebo-controlled trial settings. In terms of
vaccines, there are at least 115 vaccine candidates in development
with a number of these already initiated in human trials, however
we expect vaccines to be available to people under emergency use
only in early 2021 (Callaway, 2020; Thanh Le et al., 2020).
Overall, there are a number of concerns in relation to
the design of various trials and interpretation of the data
investigating different pharmacological agents for the treatment
of COVID-19. Some of these limitations include small cohort
sizes, no placebo control arm, lack of considerations for
gender, comorbidities, concurrent treatments, route of drug
delivery, primary outcomes lacking effects on the viral load
or suppression, and adverse drug effects. Whilst most of these
therapies represent supportive and symptomatic care, there
are a number of adjunctive therapies such as corticosteroids,
immunomodulatory, and immunoglobulin agents that have been
investigated with limited results. In particular, corticosteroids are
not recommended for the management of COVID-19 because of
the associated adverse effects, which potentially include increased
viral load, secondary infections and complications, similarly
to what was observed previously in influenza, SARS-CoV and
MERS-CoV infections (Russell et al., 2020). Potential benefits
in severe COVID-19 cases are emerging with IL-6 monoclonal
antibody, Tocilizumab, and the use of convalescent plasma or
hyperimmune immunoglobulins, however better designs and
further trials are needed for this to be established (Chen L. et
al., 2020; Fu et al., 2020). Nevertheless, none of these therapies
are capable of lung tissue repair and regeneration, particularly
in those patients with complications such as ARDS, which is
why the use of stem cell-based therapies could be beneficial in
COVID-19 patients with respiratory complications.
ARE STEM CELLS A SOLUTION TO
COVID-19 CRISIS?
MSCs could be themost promising candidate for the treatment of
SARS-CoV-2 infections (Table 1). Since the key for the treatment
of SARS-CoV-2 infection lies in the management of the cytokine
storm in the lungs, MSCs are well-suited considering their
main mechanism of action is through their immunomodulatory
and anti-inflammatory properties (Fatima et al., 2017). The
safety profile and efficacy of MSCs are well-established based
on the results from a number of completed clinical studies
investigating the therapeutic potential of these therapies in
lung diseases such as ARDS (Matthay et al., 2019; Chen J.
et al., 2020) and bronchopulmonary dysplasia (Namba, 2019),
cardiovascular diseases (Kim et al., 2015; Suvakov et al., 2020),
diabetes (Thakkar et al., 2015; Cho et al., 2018), and spinal cord
injury (Xu and Yang, 2019).
Other types of stem cells investigated for potential treatment
of SARS-CoV-2 infections include genetically engineered human
induced pluripotent stem cells (iPSC). A recent study presented
a deleterious effect on the cells in vitro when iPSCs were exposed
to SARS-CoV-2, where the pluripotency of iPSCs was lost leading
to fibroblast-like phenotype (Zebin et al., 2020). Therefore,
evidence-based selection of stem cell type for the treatment of
COVID-19 is critical for safety and efficacy.
ADVANCING STEM CELLS TO
MAINSTREAM MEDICINES FOR COVID-19
Currently, there are 17 clinical trials investigating the therapeutic
potential of MSCs in COVID-19 patients that are registered on
clinicaltrials.gov website; most of these trials are either recruiting
patients or have not yet started the recruitment. The vast
majority of the trials are selecting patients with COVID-19 and
pneumonia, and utilizing allogeneic bone-marrow or umbilical
cord-derived MSCs transplanted intravenously on three different
occasions (Table 1). Approximately 50% of the trials are being
carried out in China. Three trials (NCT03042143 already
recruiting in Northern Ireland, United Kingdom; NCT04333368
planned in France and NCT04345601 in the United States of
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TABLE 1 | Selected clinical studies using stem cells for the treatment of SARS-CoV-2 infection.
Cell type Dosage Number of
patients













reduced TNF-α, increased IL-10
and VEGF)
Complete Leng et al., 2020
Adipose tissue-derived
MSCs
Two serial doses of 1.5 ×
106 cells per kg, IV
Estimated: 100
patients
N/A Phase 2; Not yet
recruiting
NCT04348461




N/A Phase 1 clinical trial;
recruiting
NCT04336254
Dental pulp stem cells 1 × 106 cells per kg IV on
day 1, 3, and 7
Estimated: 24
patients
N/A Early Phase 1; Not
yet recruiting
NCT04302519
Wharton’s Jelly MSCs 3 doses of 1 × 106 cells per













N/A Phase 1 clinical trial;
recruiting
NCT04252118
Umbilical cord MSCs 9.9 × 107 cells IV on day 1,
3, 5, and 7
Estimated: 10
patients
N/A Phase 2 clinical trial;
recruiting
NCT04269525
Umbilical cord MSCs 0.5 × 106 cells per kg body




N/A Not yet recruiting NCT04273646










3 cohorts who receive
doses of 3, 5, or 10 million
cells per kg body weight IV
Estimated: 9
patients
N/A Phase 1 clinical trial;
recruiting
NCT04331613
#NCT numbers refer to ClinicalTrials.gov Identifier numbers.
America, not yet recruiting) aim to investigate the therapeutic
potential of MSCs in SARS-CoV-2-induced ARDS. MSCs have
already been investigated in ARDS both in the pre-clinical
(Curley et al., 2013) and clinical settings (Wilson et al., 2015),
which demonstrated the ability of MSCs to promote distal lung
epithelial repair, albeit potentially limited in the presence of
hypercapnic acidosis (Fergie et al., 2019).
Whilst a number of MSC-related trials in COVID-19 patients
with respiratory complications are underway, limited reports are
available that these treatments have the potential to improve
recovery and survival of these patients. Some encouraging data
is emerging, for example in a recent study, which assessed
7 patients transplanted with intravenous MSCs (1 × 106 per
kg) and 3 patients in the placebo controlled group albeit
consisting of all female patients, showed significant improvement
in pulmonary function and symptoms as well as substantial
reduction in inflammation compared to the placebo controlled
group (Figure 2).
Despite the lack of convincing evidence in support of MSC-
based therapies for respiratory complications of COVID-19,
a number of promising trials are currently underway, which
could revolutionize the treatment prospects for severe COVID-
19 patients. Regardless of the urgency of the need for MSC-based
therapies for COVID-19, it is critical that the production ofMSCs
is in compliance with good manufacturing practices (GMP) and
FIGURE 2 | Outcomes of MSCs treatment for COVID-19 patients reported in
pilot clinical trial: ChiCTR2000029990.
follows strict regulations prior to being approved for the use
in humans. The use of unauthorized and unapproved stem cell
therapies not validated through stringent multicenter clinical
trials should be strongly discouraged. At the same time current
findings imply that there is a need for globally coordinated
approach and support to conduct multicenter clinical trials to
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demonstrate safety and effectiveness of various types of stem cells
to treat COVID-19-induced health complications. It also suggests
that there is a need in biomedical research and development
to establish the most effective stem cell types that are ideally
suited for the treatment of aforementioned complications. These
developments will also require (a) GMP compliant technologies
to mass produce stem cells, and (b) testing platforms that mimic
human pathophysiology (e.g., 3D bioprinted organoids, organ-
on-chip) to allow high-throughput screening and rapid testing of
stem cells safety and efficacy.
Extracellular vesicles (EVs) are emerging as an attractive
alternative to the whole cell–based therapy. EVs have several
advantages compared to the whole cell therapy including lower
risk of tumorigenic effects, lower susceptibility to damage by
hostile disease microenvironment and possibility for long-term
storage. The long-term storage is fundamental to make the
treatment accessible in developing countries and it circumvents
the need to have expensive GMP cell manufacturing facilities
on-site. Nevertheless, production of EVs must follow the
same strict guidelines that apply to stem cells and any EV-
based therapy needs to be approved by the governing bodies
after being tested in clinical trials to demonstrate the safety
and efficacy.
FACTORS AFFECTING THE QUALITY
OF MSC
The successful translation of MSC-based therapies into the clinic
for treatment of COVID-19-induced lung injuries is dependent
on a number of factors. In addition to desirable therapeutic
effects, it is also important to understand the mechanism of
action and the influence of various in vivo environments on
the integrity of these cells. Stem cells can be environmentally
preconditioned by certain stimuli such as hypoxia or ischemia,
which can induce certain signaling pathways to improve
engraftment, survival, and function of transplanted cells in harsh
environments within the injured lung (Sart et al., 2014; Kim et al.,
2015; Saparov et al., 2016). Other methods of preconditioning
stem cells include the formation of three-dimensional stem cell
aggregates that lead to enhanced extracellular matrix secretion,
anti-inflammatory properties and cell survival (Bartosh et al.,
2010; Sart et al., 2014). Pre-treatment of MSCs with various
pharmacological factors can, in fact, improve therapeutic effects
and tissue repair capabilities (Hu and Li, 2018).
Furthermore, bioengineering approaches such as the use
of bioreactors can overcome the limitations of a large scale
production of stem cells necessary for transplantation and
maintenance of the stemness during and after delivery to patients
(Madl et al., 2018). Therefore, these technologies can accelerate
the transition from bench to bedside without compromising
the quality of the stem cells reaching patients. For example,
tuneable materials can be used as an artificial niche to expand
or differentiate stem cells to mature cell types (Yang et al.,
2014; Madl et al., 2017). Materials such as hydrogels used as
carriers for stem cells can also lead to enhanced regenerative
response by regulating fate and activity of transplanted stem cells
(Engler et al., 2006; Chaudhuri et al., 2016). These approaches are
currently less widely used for pulmonary applications compared
to other target organs and thus future investigations will lead to
innovative solutions.
IS THE TREATMENT EFFICACY
DEPENDENT ON THE DELIVERY ROUTE?
In the majority of clinical trials investigating the treatment
of SARS-CoV-2 infections so far, MSCs are delivered via the
intravenous route. Since intravenous route does not specifically
target lungs, the inhalation route that delivers cells directly to
lungs could be more effective. However, uniform delivery of
cells to lungs through inhalation is technically challenging (Kim
et al., 2016; Kim and Chrzanowski, 2019). Strong evidence is
emerging to suggest that the therapeutic potential of MSCs is
attributed mostly to their secreted EVs via paracrine effects,
and MSCs could also be referred to as medicinal signaling
cells (Bjørge et al., 2018; Kim et al., 2019). Delivery of
EVs to lungs is feasible and exogenous EVs can facilitate
prompt activity directly at the injured site. There is a pilot
clinical study that intends to deliver MSC-derived exosomes
via the inhalation route to patients with severe pneumonia
arising from SARS-CoV-2 infection (NCT04276987). In this
clinical trial, the main advantage of administering MSC-derived
exosomes via inhalation route compared to the intravenous
administration is the prevention of their aggregation within the
injured microcirculation. In addition, MSC-derived exosomes
have other advantages over MSCs including lower or no risk of
mutagenicity and oncogenicity as well as the storage stability of
several weeks or months facilitating less urgent transportation
and administration. A recent study using animal models of
pulmonary fibrosis also demonstrated therapeutic potential of
inhaled lung spheroid cell-secretome and exosomes for lung
regeneration (Dinh et al., 2020). While the intravenous route
is the most widely used often for the ease of administration
albeit invasive, the route of cell delivery should be tailored
according to the disease in question and patient’s circumstances
(Kim and Chrzanowski, 2019). As evident from a number
of clinically available inhaled medications for chronic lung
disease, the inhalation route of delivering therapeutics to the
lungs is a more direct route with lower incidence of adverse
effects, compared to the intravenous route. Nevertheless, the
environment in the hospital has to be appropriately managed for
inhaled administration of a treatment in COVID-19 patients. A
number of studies have demonstrated the feasibility of delivering
stem cells via spray for direct pulmonary delivery with high
viability (Kardia et al., 2016; Kim et al., 2016; Skolasinski
et al., 2020). Inhalation route of stem cell administration is an
opportunity for efficient delivery of stem cells directly to the
lungs, yet it remains an under-explored research area in the field.
THE FUTURE OF STEM CELLS FOR THE
TREATMENT OF SARS-COV-2 AND OTHER
CORONAVIRUSES INFECTIONS
Although only a limited number of MSC-based clinical
trials have been completed to date, in a small number of
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COVID-19 patients, the prospects of using these cells in
the clinical setting to treat and prevent COVID-19-induced
lung damage appear promising. Successfully completed Phase
I trials for the treatment of ARDS and emerging promising
preliminary results from current trials will soon shed light on
the effectiveness of MSCs for the treatment of SARS-CoV-
2. The proposed clinical study that aims to deliver MSC-
derived exosomes via the inhalation route to COVID-19 patients
(NCT04276987) will potentially be a paradigm shift. In the
light of a recent study that demonstrated efficacy of inhaled
stem cell-derived therapy in both ex vivo and animal models
of pulmonary fibrosis (Dinh et al., 2020), the inhalation route
due to advantages outlined above, may become more routinely
investigated along with the conventional intravenous route.
Importantly, regardless of the route of delivery and type of
stem cells, larger-scale clinical trials strictly designed with
the placebo arm and patient randomization are necessary to
achieve successful stem cell-based therapies for the treatment
of COVID-19.
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